Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan lifts Ocado price target, reiterates 'overweight'

(Sharecast News) - JPMorgan Cazenove reiterated its 'overweight' rating on Ocado on Friday and lifted the price target to 437p from 400p. It said the company's operational performance, particularly within its Technology Solutions segment, continues to improve, while bearish arguments are increasingly losing traction.

JPM said that after changing its view on Ocado earlier this year and turning OW for the first time since 2018, it now sees more and more data points for improvements in operational performance coming through that should drive a continued, sustained re-rating.

The bank noted that the current pipeline of eight new customer fulfilment centres (CFC) ramp-ups scheduled for 2025-2027 is largely de-risked, providing visibility into Technology Solutions revenue growth.

"Coupled with stringent cost management, including reduced technology and support expenses, we project a group EBITDA compound annual growth rate of 43% for 2024-2027E and estimate underlying free cash flow break-even by H2 2026, in line with management guidance," it said.

JPM also pointed out that the retail operations - now consolidated under Marks & Spencer - have emerged as the fastest-growing UK retailer, with a 16.3% revenue increase in the first half, driven by a 13% rise in customer growth year-on-year.

The bank said the cost for potential clients of deploying capital Ocado's Solutions has decreased significantly.

"Ocado can now initiate new partnerships with 2-3 modules, versus 6+ modules two years ago, thereby reducing risk for clients," it said.

Finally, JPM argued that the balance sheet is now manageable with no further refinancing requirements in the next three years, dismissing a key concern from investors.

The bank's new Nov-26 price target assumes an additional 20 modules from new signings beyond 2027 which it sees as conservative.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.